UAB 18106:OXEL: A pilot study of immune checkpoint or capecitabine or combination therapy as adjuvant therapy for triple negative breast cancer with residual disease following neoadjuvant chemotherapy

Grant

Awarded By

Total Award Amount

  • 26696.00
  • Direct Costs

  • 20535.00
  • Sponsor Award Id

  • Contributor

  • Erica Stringer-Reasor M.D.   Principal Investigator